System for sustained-release delivery of anti-inflammatory agents from a coated medical device
AssigneeControl Delivery Systems, Inc.
InventorsPaul Ashton, Jianbing Chen
Life of this patent
Estimating the term…
Abstract
The subject invention provides medical devices having a coating disposed on at least one surface, wherein the coating includes a polymer matrix and a low solubility anti-inflammatory corticosteroid formulation, or low solubility codrug or prodrug of an anti-inflammatory corticosteroid formulation.
Claims44
A medical device comprising:
- (a) a substrate having a surface;
- and
- (b) a coating disposed on the surface, said coating comprising a polymer matrix including an anti-inflammatory corticosteroid, or a codrug or prodrug thereof, which corticosteroid is formulated in a form having a solubility less than 0.1 mg/mL in water at 25° C.,
- wherein the corticosteroid is released from said polymer matrix at a rate of release to produce an effective concentration of said corticosteroid in tissue or biological fluid in which the medical device is implanted.
A medical device comprising:
- (a) a substrate having a surface;
- and
- (b) a coating disposed on the surface, said coating comprising a polymer matrix including a soluble anti-inflammatory corticosteroid, and one or more additives which decrease the rate of release of the corticosteroid into the biological fluid or tissue surrounding the device,
- wherein the corticosteroid is released from said polymer matrix at a rate of release to produce an effective concentration of said corticosteroid in tissue or biological fluid in which the medical device is implanted.
A medical device comprising:
- (a) a substrate having a surface;
- and
- (b) a coating disposed on the surface, said coating comprising a polymer matrix including a prodrug, wherein said prodrug is represented by the general formula A-L-B, in which
- A represents an anti-inflammatory corticosteroid or a prodrug thereof;
- L represents a covalent bond or covalent linker linking A and B to form the prodrug, wherein the bond or linker is metabolized under physiological conditions;
- and
- B represents a moiety which, when linked to A, results in a compound having an optimized solubility for sustained delivery in vivo from the coated device.
A medical device comprising:
- (a) a substrate having a surface;
- and
- (b) a coating disposed on the surface, said coating comprising a polymer matrix including a low solubility prodrug, wherein said prodrug is represented by the general formula of A::B, in which
- A represents an anti-inflammatory steroid or a derivative thereof;
- ::
- represents an ionic bond between A and B that dissociates under physiological conditions to generate said pharmaceutically active form of A;
- and
- B represents a moiety which, when linked to A, results in a compound having an optimized solubility for sustained delivery in vivo from the coated device.
A medical device comprising:
- (a) a substrate having a surface;
- and
- (b) a coating disposed on the surface, said coating comprising a polymer matrix including triamcinolone acetonide.
A method of manufacturing a coating for a medical device, comprising admixing a polymer matrix and a pharmaceutically effective amount of an anti-inflammatory corticosteroid, or a codrug or prodrug thereof, which corticosteroid is formulated in a form having a solubility less than 0.1 mg/mL in water at 25° C.
A use of a polymeric coating in the manufacture of a device to place in a patient for treatment of said patient with a sustained dosage regimen of an anti-inflammatory corticosteroid, which corticosteroid is formulated in a form having a solubility less than 0.1 mg/mL in water at 25° C.
Dependencies are inferred from the claim text.